OrbusNeich Medical Group Holdings Limited (Stock Code: 6929) has announced that its board of directors will convene on March 12, 2026. The agenda includes reviewing and approving the annual results for the fiscal year ended December 31, 2025, considering a final dividend if applicable, and discussing any other pending matters.
This announcement indicates that the company’s leadership, chaired by Mr. David Chien, will assess the performance of the past financial year, which concluded on December 31, 2025. The directors will also deliberate on the distribution of dividends, subject to final approval. The conclusions from this meeting are expected to be disclosed following the formal board review.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.